Pricing
  1. US-listed companies
  2. HALOZYME THERAPEUTICS, INC.
  3. Financials
  4. Revenue growth (%)

HALOZYME THERAPEUTICS, INC. (HALO)

Market cap
$7.9B
P/E ratio
SummaryFinancials
Period EndRevenue growth (%) YoY (%)
Dec 31, 202422.4-12.41%
Dec 31, 202325.6-47.62%
Dec 31, 202248.9-25.52%
Dec 31, 202165.7+79.77%
Dec 31, 202036.5+25.71%
Dec 31, 201929.1-155.84%
Dec 31, 2018-52-144.92%
Dec 31, 2017115.8+1245.41%
Dec 31, 20168.6-89.14%
Dec 31, 201579.3+111.58%
Dec 31, 201437.5+27.15%
Dec 31, 201329.5-220.09%
Dec 31, 2012-24.5

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat